Global Balantidiasis Market Overview
The balantidiasis market is anticipated to reach USD 1,743.0 Million by 2030 at 7.20% CAGR during the forecast period 2022-2030. Balantidiasis, also known as Balantidium coli infection, is a disease caused by intestinal protozoan parasite Balantidium coli. Being transmitted through the fecal-oral route, a person acquires the disease by ingesting infective cysts from food and water contaminated by feces.
The disease mainly affects large intestine. Diarrhea, weight loss, dysentery, abdominal pain, nausea, and vomiting are common symptoms for balantidiasis. The diseases is found to be prevalent in the rural areas of the developed and developing countries due to the contamination of water by the fecal matter of pigs or humans. The best remedy for the prevention of the disease are maintaining proper conditions for clean and safe drinking water. Antibiotics are most widely used for the treatment of balantidiasis.
Rising prevalence of gastrointestinal disorders, increasing number of patients and availability of treatment of balantidiasis drives the growth of the market. Additionally, the lack of hygiene and sanitation in the rural areas of developing countries is one of the many factors which affect the spread of this disease. Furthermore, rising awareness about the diseases transmitted through fecal-oral route influences the market growth. Competition among existing market players restrict the entry of new players.
Some of the key players in Balantidiasis Market are:
Intended Audience
The balantidiasis market is segmented on the basis of diagnosis, treatment, and end user.
On the basis of diagnosis, the market is segmented into stool examination, sigmoidoscopy, biopsy, and others.
On the basis of treatment, the market is segmented into antibiotics, appendectomy, and others. Antibiotics segment is further divided into tetracycline, metronidazole, and others.
On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
The market for balantidiasis is found to be steady in Americas. The disease is less prevalent in North America due to high quality standards, negligible number of cases, and hygienic environment. Furthermore, emphasis on healthy life style and prevention of communicable diseases also influence the growth of the market. The prevalence of the disease is found to the higher rural South America than North American countries.
In Europe, the prevalence of balantidiasis is found to be low. Rising importance of hygienic food products and water, rigorous quality checks, rising expenditure on healthcare, and availability of funds boost the growth of the Balantidiasis Market.
In Asia Pacific, the prevalence of balantidiasis is found increasing steadily as a result of increasing prevalence of colitis, chronic diarrhea, and, deep intestinal ulcerations and poor hygienic conditions in developing countries. The infection is found to be sub clinical leading to the development of diarrhea leading to the perforation of colon. Furthermore, poor healthcare system in developing countries boost the market growth. Furthermore, the burden of gastrointestinal diseases is attributed to an increase in age, high prevalence of H pylori and lifestyle changes with risk factors such as smoking and obesity. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence for Asia Pacific was 15.8 and mortality was 11.7 per 100,000. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.
The Middle East & African region has high prevalence of balantidiasis. The infection is mainly acquired due to ingestion of food and water contaminated by cysts. Furthermore, gastrointestinal diseases are a major cause of disability in the Middle East & Africa. In Africa, the Balantidiasis Market is driven by rising demand for primary care services and improving healthcare system.
FIGURE 1: Global Balantidiasis Market by Region, 2016 (%) 
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation.
Balantidiasis Market, by Region
Research Methodology 
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation.
| Report Attribute/Metric | Details |
| Market Size | USD 1,743.0 Million by 2030 |
| CAGR | 7.20% (2022-2030) |
| Base Year | Â Â 2021 |
| Forecast Period | Â Â 2022-2030 |
| Historical Data | Â Â 2020 |
| Forecast Units | Â Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, end user, Region |
| Geographies Covered | America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc. (U.K), BD (U.S.), Sandoz International GmbH (Germany), Amneal Pharmaceuticals LLC. (U.S.), Akorn, Inc. (U.S.), and PharmaDerm, a division of Fougera Pharmaceuticals Inc. (U.S.) |
Balantidiasis Market Highlights:
Frequently Asked Questions (FAQ) :
Balantidiasis market is expected to expand at 7.20% CAGR from 2022 to 2030.
Rising prevalence of gastrointestinal disorders, availability of treatments for balantidiasis, and a large patient pool are the biggest growth drivers of the global balantidiasis market.
APAC can display a robust growth rate for the global balantidiasis market till 2030.
The Middle East & Africa can fetch maximum revenue for the global balantidiasis market due to high prevalence of the disease in both these regions.
BD, Pfizer, GlaxoSmithKline plc., Abbott, Sandoz International GmbH, PharmaDerm, Amneal Pharmaceuticals LLC, and Akorn, Inc. are notable players of the global balantidiasis market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
